Advanced search
Publication Cover
Risk Management and Healthcare Policy Volume 17, 2024 - Issue
Submit an article Journal homepage
42
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis

Hongchao Li1 School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, People’s Republic of ChinaView further author information
,
Wei He2 Fertility and Reproductive Medicine Centre, The Southwest Hospital of AMU, Chongqing, 400038, People’s Republic of ChinaView further author information
,
Hongbo Lin3 Department of Reproductive Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, People’s Republic of ChinaView further author information
,
Angying Du4 Merck Serono, an Affiliate of Merck KGaA Darmstadt Germany, Beijing, 100016, People’s Republic of ChinaView further author information
,
Xue Zhang5 Real-World Solutions, IQVIA, Shanghai, 200041, People’s Republic of ChinaView further author information
,
Han Yang5 Real-World Solutions, IQVIA, Shanghai, 200041, People’s Republic of ChinaView further author information
&
Shuli Qu5 Real-World Solutions, IQVIA, Shanghai, 200041, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1387-1394 | Received 02 Feb 2024, Accepted 29 Apr 2024, Published online: 27 May 2024

References

  • Zhao Y, Fu H. Social egg freezing for single women in china: legal and ethical controversies. Risk Management and Healthcare Policy. 2023;Volume 16:2379–2389. doi:10.2147/RMHP.S424361
  • Logan S, Gu R, Li W, Xiao S, Anazodo A. Infertility in China: culture, society and a need for fertility counselling. Asian Pac J Reprod. 2019;8:1–6. doi:10.4103/2305-0500.250416
  • Zhou Z, Zheng D, Wu H, et al. Epidemiology of Infertility in China: A Population-Based Study. Vol. 125. BJOG; 2018:432–441.
  • Hovatta O, McVeigh E, Lass A, Homburg R. A large Northern European observational study of follitropin alpha filled-by-mass pre-filled pen. Reprod Biomed Online. 2009;18:502–508. doi:10.1016/S1472-6483(10)60126-5
  • Germond M, Urner F, Chanson A, Primi MP, Wirthner D, Senn A. What is the most relevant standard of success in assisted reproduction? The cumulated singleton/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA. Hum Reprod. 2004;19:2442–2444. doi:10.1093/humrep/deh501
  • Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? Hum Reprod. 2015;30:2703–2707. doi:10.1093/humrep/dev263
  • Lass A, McVeigh E. Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. R Reprod Biomed Online. 2004;9:604–610. doi:10.1016/S1472-6483(10)61768-3
  • Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod. 1999;14:2207–2215. doi:10.1093/humrep/14.9.2207
  • Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr Med Res Opin. 2003;19:41–46. doi:10.1185/030079902125001344
  • Bassett R, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online. 2005;10:169–177. doi:10.1016/S1472-6483(10)60937-6
  • Yang R, Liang XY, Zhu YM, et al. Clinical application of domestic recombinant human follicle-stimulating hormone in controlled ovarian hyperstimulation with assisted reproductive technology. Chin J Reprod Contracep. 2021;41:113–119.
  • Zegers-Hochschild F, Adamson GD, Dyer S, et al. The international glossary on infertility and fertility care. Hum Reprod. 2017;32:1786–1801. doi:10.1093/humrep/dex234
  • Ku PY, Lee RK, Lin SY, Lin MH, Hwu YM. Comparison of the clinical outcomes between fresh blastocyst and vitrified-thawed blastocyst transfer. J Assist Reprod Genet. 2012;29:1353–1356. doi:10.1007/s10815-012-9874-z
  • Olivius C, Lundin K, Bergh C. Predictive factors for live birth in cryopreservation single embryo transfer cycles. Reprod Biomed Online. 2008;17:676–683. doi:10.1016/S1472-6483(10)60315-X
  • Liu FH, Yang YZ, Zhang SY, Qiao J, Liu JY. A consensus of diagnosis and treatment for complications during assisted reproductive technology. Reprod Contracep. 2015;35:431–439.
  • Chua SJ, Mol BW, Longobardi S, et al. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2021;19:51. doi:10.1186/s12958-021-00727-y
  • Xue W, Lloyd A, Falla E, Roeder C, Papsch R, Bühler K. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. Int J Womens Health. 2019;11:319–331. doi:10.2147/IJWH.S193048
  • Gizzo S, Ferrando M, Lispi M, Ripellino C, Cataldo N, Bühler K. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany. Italy and Spain J Med Econ. 2018;21:1096–1101. doi:10.1080/13696998.2018.1511567
  • Silverio N, Botica F, Batista AR. Cost-effectiveness of recombinant human follicle stimulating hormone biosimilars in Portugal. Value Health. 2016;19:A402–A403. doi:10.1016/j.jval.2016.09.323

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.